Inventiva price target lowered to $24 from $36 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Inventiva to $24 from $36 and keeps a Buy rating on the shares after the company provided an update on the status of the Phase 3 NATiV3 clinical trial of lanifibranor and other clinical development updates. The “most important” update was that the topline results of NATiV3 are now expected in the first half of 2026, versus the second half of 2025 previously, says the analyst, who notes that this is the third such delay on the timeline of NATiV3’s results. The firm views yesterday’s “disappointing update as testing investors’ patience, while eroding our confidence in the trial’s execution,” the analyst tells investors.